论文部分内容阅读
对９８例原发性肝癌随机分为２组，治疗组５０例，给予肝动脉栓塞化疗（ＴＡＥ）加腹腔化疗。对照组４８例仅给予ＴＡＥ治疗，２组有效率分别为５２．０％和２９．１７％，Ｐ＜０．０５。ＴＡＥ可引起肝癌的坏死和缩小，为中晚期肝癌的首选疗法。腹腔化疗药物经腹腔吸收入门静脉，可作为门静脉化疗的一种改良方法，为腹腔、门静脉和肝脏提供恒定和持久的高药物浓度，杀死残存肿瘤细胞，显著提高疗效。
98 cases of primary liver cancer were randomly divided into 2 groups, 50 cases of treatment group, and hepatic artery embolization chemotherapy (TAE) plus intraperitoneal chemotherapy. In the control group, only 48 cases were treated with TAE. The effective rates in the two groups were 52.0% and 29.17%, respectively, P<0.05. TAE can cause necrosis and shrinkage of liver cancer, and it is the first choice for advanced liver cancer. Intraperitoneal chemotherapeutic drugs that absorb portal veins in the abdominal cavity can be used as an improved method for portal vein chemotherapy, providing constant and long-lasting high drug concentrations for the abdominal cavity, portal vein and liver, killing residual tumor cells, and significantly improving efficacy.